JinkoSolar's majority-owned subsidiary, Jiangxi Jinko, announced a preliminary unaudited net loss ranging from RMB2.98 billion to RMB3.58 billion for the nine months ending September 30, 2026. Excluding extraordinary items, the loss could be between RMB3.81 billion and RMB4.41 billion. These figures differ from JinkoSolar's consolidated results due to different accounting standards and scope. Investors are cautioned not to rely solely on these preliminary numbers as the company continues to operate globally in clean energy and emerging technologies.
JinkoSolar's subsidiary Jiangxi Jinko reported preliminary unaudited net losses for the nine months ended September 30, 2026. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 16, 2026 16:11 WIB: Of 83 priced US stocks, 56 rose and 23 fell. Notable movers include USAS at USD 3.94 (+2.07%), AA at USD 41.22 (+1.97%) with 100% buy orders, and AYA at USD 26.45 (+1.73%), each with a typical hold time of 1 day on Pluang.
NeOnc Technologies reported early clinical improvement in a critically ill three-year-old boy with an aggressive brain tumor treated with investigational intranasal NEO100 under compassionate use in Abu Dhabi. The child is now breathing independently...
TransUnion's Branded Call Display, a solution that helps consumers identify legitimate callers and avoid robocall fraud, has been named one of TIME's Best Inventions of 2026 in the Connectivity & Communication category. The technology displays a busi...
La Rosa Holdings Corp. will change its name to Stratum Holdings Corp. on October 19, 2026, reflecting its shift from real estate services to an AI infrastructure company specializing in GPU leasing and high-performance computing. The company recently...
ASUS has released the ProArt P16 and P14 laptops in Canada, powered by NVIDIA RTX Spark technology. These laptops feature up to 128GB of unified memory and advanced AI capabilities designed for creators, AI developers, and workflow builders, enabling...
OXB, a global cell and gene therapy CDMO, has appointed Dr Joachim Kreuzburg as an Independent Non-Executive Director effective November 23, 2026. Dr Kreuzburg brings over 20 years of leadership in life sciences, notably transforming Sartorius AG int...
